Research on the effectiveness and tolerability of vaginal administration of probiotic Lactobacillus acidophilus in women with symptoms of colpitis

Probiotici su živi mikroorganizmi koji primijenjeni u dostatnoj količini mijenjaju sastav i metaboličku aktivnost mikroflore ili utječu na imunološki sustav što djeluje povoljno na zdravlje čovjeka. Lactobacillus acidophilus je najbolje proučena acidofilna bakterija koju prirodno nalazimo u jogurtu i acidofilnom mlijeku. Cilj ovog ispitivanja je bio istražiti djelotvornost i podnošljivost vaginalne primjene probiotika Lactobacillus acidophilus u bolesnica sa simptomima kolpitisa. U ovom prospektivnom ispitivanju djelotvornosti i podnošljivosti sedmodnevne primjene Lactobacillus acidophilus solucije za vaginalnu primjenu u žena s kolpitisom – probiotik Lactobacillus acidophilus se pokazao djelotvoran s obzirom da je 42 od ukupno 50 liječenih žena bilo klinički izliječeno. Klinički uspjeh bio je češći u žena iznad 50 godina starosti, te u žena koje su imale simptome iritacije i svrbeža. Lactobacillus acidophilus solucija za vaginalnu primjenu se pokazala izrazito podnošljiva s obzirom da niti jedna od 50 liječenih žena nije imala nuspojave liječenja.Probiotics are live microorganisms which, when administered in adequate amounts, change the structure and metabolic activity of human microflora or affect the immune system in a way beneficial for human health. Lactobacillus acidophilus is the most studied acidophilus bacteria that is naturally found in yogurt and acidophilus milk. The aim of this research was to investigate the effectiveness and tolerability of vaginal administration of probiotic Lactobacillus acidophilus in patients with symptoms of colpitis. In this prospective research on the efficacy and tolerability of Lactobacillus acidophilus vaginal solution used for 7 days in women with colpitis – probiotic Lactobacillus acidophilus has proved effective in 42 out of 50 treated women. Clinical success was more common in women over 50 years of age and in women with symptoms of irritation and pruritis. Lactobacillus acidophilus vaginal solution has proved especially tolerable since not one among 50 treated women experienced treatmant side effects

Guidelines for antimicrobial treatment and prophylaxis of urinary tract infections – year 2006

Preporuke za antimikrobno liječenje i profilaksu infekcija mokraćnog sustava (IMS) donešene su prema rezultatima ispitivanja rezistencije najčešćih uzročnika IMS na antimikrobike što ga od 1997. godine provodi Odbor za praćenje rezistencije bakterija na antibiotike u Republici Hrvatskoj. Nekomplicirani cistitis liječi se 1, 3 ili 7 dana, komplicirani cistitis 7 dana, pijelonefritis 10–14 dana, a komplicirane IMS 7 do 14 dana, rijetko duže. U liječenju cistitisa rabe se fluorokinoloni, nitrofurantoin, betalaktamski antibiotici te u područjima niže rezistencije trimetoprim/sulfametoksazol. Jednokratna terapija fluorokinolonima primjenjuje se u inače zdravih mladih žena s normalnim urotraktom u kojih su simptomi cistitisa prisutni kraće od 7 dana. Empirijska antimikrobna terapija pijelonefritisa, rekurentnih i svih kompliciranih IMS treba se revidirati nakon nalaza urinokulture. U liječenju bakterijskog prostatitisa i febrilnih IMS muškaraca lijek prvog izbora je ciprofloksacin. Asimptomatska bakteriurija (AB) liječi se u trudnica, novorođenčadi, predškolske djece s abnormalnim urotraktom, prije invazivnih uroloških i ginekoloških zahvata, u primaoca transplantiranog bubrega, u prvim danima kratkotrajne kateterizacije mokraćnog mjehura. Antimikrobna profilaksa primjenjuje se prvenstveno jedan sat prije dijagnostičkog ili terapijskog invazivnog urološkog postupka odabranim antimikrobnim sredstvima.Recommendations for antimicrobial treatment and prophylaxis of urinary tract infections (UTI) have been made according to study results on the resistance of the most frequent causative agents of UTI to antimicrobial drugs. The Committee for monitoring bacterial resistance to antibiotics in the Republic of Croatia has been conducting this study since 1997. Uncomplicated cystitis is treated for 1, 3 or 7 days, complicated cystitis for 7 days, pyelonephritis 10–14 days, and complicated UTI 7 to 14 days, rarely longer. For the treatment of cystitis the following drugs are used: fluoroquinolones, nitrofurantoin, betalactam antibiotics, and in cases of lower resistance trimethoprim-sulfamethoxazole. A single therapy with fluoroquinolones is administered to otherwise healthy young women with normal urinary tract in whom cystitis symptoms have been present for less than 7 days. Empirical antimicrobial therapy of pyelonephritis, recurrent and all complicated UTIs must be reviewed after urine culture finding is obtained. In the treatment of bacterial prostatitis and febrile UTIs in males, the drug of first choice is ciprofloxacin. Asymptomatic bacteriuria is treated in pregnant women, newborns, preschool children with urinary tract abnormalities, before invasive urological and gynecological procedures, in kidney transplant recipients, and in the first days of short-term urinary bladder catheterization. Antimicrobial prophylaxis is administered primarily one hour prior to diagnostic or therapeutic invasive urological procedures, using selected antimicrobial agents

Research on the effectiveness and tolerability of vaginal administration of probiotic Lactobacillus acidophilus in women with symptoms of colpitis

Probiotici su živi mikroorganizmi koji primijenjeni u dostatnoj količini mijenjaju sastav i metaboličku aktivnost mikroflore ili utječu na imunološki sustav što djeluje povoljno na zdravlje čovjeka. Lactobacillus acidophilus je najbolje proučena acidofilna bakterija koju prirodno nalazimo u jogurtu i acidofilnom mlijeku. Cilj ovog ispitivanja je bio istražiti djelotvornost i podnošljivost vaginalne primjene probiotika Lactobacillus acidophilus u bolesnica sa simptomima kolpitisa. U ovom prospektivnom ispitivanju djelotvornosti i podnošljivosti sedmodnevne primjene Lactobacillus acidophilus solucije za vaginalnu primjenu u žena s kolpitisom – probiotik Lactobacillus acidophilus se pokazao djelotvoran s obzirom da je 42 od ukupno 50 liječenih žena bilo klinički izliječeno. Klinički uspjeh bio je češći u žena iznad 50 godina starosti, te u žena koje su imale simptome iritacije i svrbeža. Lactobacillus acidophilus solucija za vaginalnu primjenu se pokazala izrazito podnošljiva s obzirom da niti jedna od 50 liječenih žena nije imala nuspojave liječenja.Probiotics are live microorganisms which, when administered in adequate amounts, change the structure and metabolic activity of human microflora or affect the immune system in a way beneficial for human health. Lactobacillus acidophilus is the most studied acidophilus bacteria that is naturally found in yogurt and acidophilus milk. The aim of this research was to investigate the effectiveness and tolerability of vaginal administration of probiotic Lactobacillus acidophilus in patients with symptoms of colpitis. In this prospective research on the efficacy and tolerability of Lactobacillus acidophilus vaginal solution used for 7 days in women with colpitis – probiotic Lactobacillus acidophilus has proved effective in 42 out of 50 treated women. Clinical success was more common in women over 50 years of age and in women with symptoms of irritation and pruritis. Lactobacillus acidophilus vaginal solution has proved especially tolerable since not one among 50 treated women experienced treatmant side effects

Incidence, Epidemiology, and Characteristics of Quinolone- Nonsusceptible Streptococcus pneumoniae in Croatia

Among 585 Streptococcus pneumoniae strains isolated in 22 Croatian hospitals 21 strains (3.6%) were quinolone nonsusceptible. MICs of all quinolones were high for seven strains tested with the same serotype (23F) and mutations in gyrA, parC, and parE. The remaining 14 strains were more heterogeneous and had mutations only in parC and/or parE, and the MICs of quinolones were lower for these strains

Global Distribution and Epidemiologic Associations of Escherichia coli Clonal Group A,

Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this Journal-based CME activity for a maximum of 1 AMA PRA Category 1 Credit(s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other clinicians completing this activity will be issued a certifi cate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 70 % minimum passing score and complete the evaluation at www.medscape.org/journal/eid; (4) view/print certifi cate

Carbapenemase-producing enterobacteriaceae in Europe: a survey among national experts from 39 countries, february 2013

The spread of carbapenemase-producing Enterobacteriaceae (CPE) is a threat to healthcare delivery, although its extent differs substantially from country to country. In February 2013, national experts from 39 European countries were invited to self-assess the current epidemiological situation of CPE in their country. Information about national management of CPE was also reported. The results highlight the urgent need for a coordinated European effort on early diagnosis, active surveillance, and guidance on infection control measures

Carbapenemase-producing Enterobacteriaceae in Europe: A survey among national experts from 39 countries, February 2013

The spread of carbapenemase-producing Enterobacteriaceae (CPE) is a threat to healthcare delivery, although its extent differs substantially from country to country. In February 2013, national experts from 39 European countries were invited to self-assess the current epidemiological situation of CPE in their country. Information about national management of CPE was also reported. The results highlight the urgent need for a coordinated European effort on early diagnosis, active surveillance, and guidance on infection control measures